Persistent Epithelial Defect Drugs Market Size 2032 | Dompe Farmaceutici, OcuNexus Therapeutics/Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others.

DelveInsight's "Persistent Epithelial Defect Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Persistent Epithelial Defect (PEDs), historical and forecasted epidemiology as well as the Persistent Epithelial Defect (PEDs) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Takeaways from the Persistent Epithelial Defects Market Report
• The increase in Persistent Epithelial Defect market size is a direct consequence of expected approval of emerging therapies and the increasing awareness of Persistent Epithelial Defect in the 7MM.
• As per DelveInsight analysis, the total Persistent Epithelial Defect Incident Cases in the 7MM were found to be approximately 242,647 cases in 2021, which are expected to increase by 2032.
• According to estimates based on DelveInsight's analysis, the US accounted for nearly 42.7% of the total Incident Cases of PCED in the 7MM in the year 2021, which are expected to increase further by 2032.
• According to estimates based on DelveInsight's epidemiology model for PCED, the gender distribution of the disease suggests a male predominance across the 7MM, with approximately 62,105 male and 41,403 female cases in the US in 2021.
• According to DelveInsight estimates, males are more affected with PCED than females in the 7MM.
• The leading Persistent Epithelial Defect Companies such as Dompe Farmaceutici, OcuNexus Therapeutics/Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others.
• Promising Persistent Epithelial Defect Therapies such as KIO-201, DE-105 ophthalmic solution, lufepirsen, ST266, Nexagon® (lufepirsen) High Dose Concentration, and others.

Discover which therapies are expected to grab the Persistent Epithelial Defect Market Share @ Persistent Epithelial Defect Market Outlook- https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Persistent Epithelial Defect Overview
A Persistent Epithelial Defect (PED) refers to a condition where the epithelial layer of the cornea (the clear, outer layer) fails to heal properly over time, leading to a persistent open wound on the surface of the eye. Persistent corneal epithelial defect (PEDs or PCEDs) are corneal defects that result from the failure of rapid re-epithelialization and closure after a corneal injury, despite two weeks of standard supportive treatment. In addition to causing compromised vision and ocular discomfort, non-healing corneal epithelial defects has other deleterious consequences, including infection, scarring, melting, and perforation. The condition is common in individuals with metaherpes, neurotrophic keratopathy, or diabetic keratopathy.

Persistent Epithelial Defect Epidemiology Insights
• Total Persistent Epithelial Defect Incident Cases
• Persistent Epithelial Defect Etiology-specific Incident Cases
• Persistent Epithelial Defect Gender-specific Incident Cases

Download the report to understand which factors are driving Persistent Epithelial Defect Epidemiology trends @ Persistent Epithelial Defect Epidemiological Insights- https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Persistent Epithelial Defect Market Insights
Corneal epithelial defects, though seemingly small, require careful attention and effective treatment for optimal healing and prevention of complications. The treatment and management of these defects involve a multifaceted approach that combines innovative techniques and patient-centered care. From the simple yet powerful act of frequent lubrication with eye drops to promote healing, to the implementation of therapeutic bandage contact lenses that serve as guardians of the delicate cornea, every step aims to restore the epithelium's integrity.

Persistent Epithelial Defect Treatment Landscape
The standard medical treatment protocol begins with aggressive lubrication using preservative-free artificial tears and sterile ocular ointments. They provide a setting in which the epithelium can reestablish standard structure and function. It is critical to discontinue all concurrent medications that may disrupt or delay re-epithelialization. Many commercial artificial tears contain preservatives, most commonly benzalkonium chloride, to prevent contamination with bacteria and fungi. These preservatives are known to irritate the eyes and, if used frequently, can cause ocular toxicity and epithelial damage. As a result, it is advisable to use preservative-free lubricants.

Persistent Epithelial Defect Emerging Therapies
• KIO-201
• ST266

Persistent Epithelial Defect Drugs Uptake
• Nexagon (lufepirsen ophthalmic gel) being developed by Amber Ophthalmics , is a first-in-class, patent protected product to redefine the PCED treatment paradigm. It is a proprietary, unmodified antisense oligonucleotide that inhibits the hemichannel forming protein, connexin43 (Cx43). It inhibits hemichannel formation, arresting an exaggerated inflammatory cascade, attenuating cytokine-induced cell death, restoring homeostasis and preserving corneal epithelium, and restorings limbal stem cell function to promote healing. The US FDA has granted it Orphan drug designation for PCED. Amber announced positive results of Nexagon (lufepirsen ophthalmic gel) in Phase II trials for the treatment of PCED and has started recruiting for Phase II/III trials, NEXPEDE-1 study.

• ST266, developed by Noveome Biotherapeutics, is a first-of-its-kind multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. In its preclinical studies ST266 reduced eye inflammation in damaged corneas and enhanced re-epithelialization by cells that form the cornea. Recently, Noveome announced positive data for its Phase II clinical trial in PCED and plans to initiate a Phase IIb trial, however there has been no recent update about the same.

• KIO-201, being developed by Kiora Pharmaceuticals, is a topical eye drop for treating PCED. KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, designed to accelerate natural corneal wound healing. It is formulated as a convenient eye drop and provides a thin coating to the surface of the eye, serving as a protectant to facilitate and accelerate corneal re-epithelization. Kiora Pharmaceuticals recently published Phase II study results at the Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans. The company has started planning discussions with the US FDA to initiate Phase III registration study in PCED.

• Kala Pharmaceuticals is developing KPI-012, a mesenchymal stem cell secretome (MSC-S) for the treatment of PCED. It recently enrolled the first patient in CHASE Phase IIb clinical trial, the first of two pivotal studies required to support an application for marketing approval in the US with results expected in 2024. It has been granted ODD by the US FDA for the same.

Persistent Epithelial Defect Companies
Dompe Farmaceutici, OcuNexus Therapeutics/Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others.

Scope of the Persistent Epithelial Defect Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Persistent Epithelial Defect Companies- Dompe Farmaceutici, OcuNexus Therapeutics/Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others.
• Persistent Epithelial Defect Therapies- KIO-201, DE-105 ophthalmic solution, lufepirsen, ST266, Nexagon® (lufepirsen) High Dose Concentration, and others.
• Persistent Epithelial Defect Market Dynamics: Persistent Epithelial Defect Market Drivers and Barriers
• Persistent Epithelial Defect Unmet Needs, KOL's views, Analyst's views, Persistent Epithelial Defect Market Access and Reimbursement

Discover more about Persistent Epithelial Defect Drugs in development @ Persistent Epithelial Defect Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Persistent Epithelial Defect (PEDs)
3. Competitive Intelligence Analysis for Persistent Epithelial Defect (PEDs)
4. Persistent Epithelial Defect (PEDs): Market Overview at a Glance
5. Persistent Epithelial Defect (PEDs): Disease Background and Overview
6. Patient Journey
7. Persistent Epithelial Defect (PEDs) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Persistent Epithelial Defect (PEDs) Unmet Needs
10. Key Endpoints of Persistent Epithelial Defect (PEDs) Treatment
11. Persistent Epithelial Defect (PEDs) Marketed Products
12. Persistent Epithelial Defect (PEDs) Emerging Therapies
13. Persistent Epithelial Defect (PEDs): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Persistent Epithelial Defect (PEDs)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330

This release was published on openPR.